

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	08/974,584	
	Filing Date	November 19, 1997	
	First Named Inventor	Cech	
	Group Art Unit	1655	
	Examiner Name	Myers, Carla J.	
Total Number of Pages in This Submission	284	Attorney Docket Number	015389-002950US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input checked="" type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Sequence Listing Computer readable form of Sequence Listing
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

LICANT, ATTORNEY, OR AGENT

LLP

Reg. No. 37,505

DISK TO STIC

DATE:

DATE OF MAILING

with the United States Postal Service with sufficient postage as first class for Patents, Washington, D.C. 20231 on this date:

November 27, 2001

Typed or printed name	Paula Faulk Hurley
Signature	<i>Paula Faulk Hurley</i>
Date	November 27, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3186177 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket No.: 015389-002950US
Client Ref. No.: 18/206P2

23/11
B. Webb
PATENT

On November 27, 2001

RECEIVED

JAN 18 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Townsend and Crew

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CECH et al.

Application No.: 08/974,584

Filed: November 19, 1997

For: TELOMERASE REVERSE
TRANSCRIPTASE

Examiner: Myers, Carla J.

Art Unit: 1655

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office communication mailed October 31, 2001, Applicants submit herewith the required paper and computer readable copies of a new Substitute Sequence Listing to replace the Substitute Sequence Listing submitted June 8, 2001. Please amend the specification and claims in adherence with 37 C.F.R. § 1.821-1.825 as follows:

IN THE SPECIFICATION:

Please cancel the present "Substitute Sequence Listing", pages 1-284, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 280, at the end of the application.

IN THE CLAIMS:

Please amend claim 105 as follows: